Xiaofan Lu

ORCID: 0000-0003-2417-6548
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Renal cell carcinoma treatment
  • Ferroptosis and cancer prognosis
  • Epigenetics and DNA Methylation
  • Renal and related cancers
  • Cancer Immunotherapy and Biomarkers
  • Radiomics and Machine Learning in Medical Imaging
  • Bladder and Urothelial Cancer Treatments
  • Cancer-related molecular mechanisms research
  • RNA modifications and cancer
  • Advanced X-ray and CT Imaging
  • Cancer Genomics and Diagnostics
  • COVID-19 Clinical Research Studies
  • Lung Cancer Diagnosis and Treatment
  • HIV Research and Treatment
  • Colorectal Cancer Screening and Detection
  • Prostate Cancer Treatment and Research
  • Sarcoma Diagnosis and Treatment
  • Thermal Regulation in Medicine
  • COVID-19 diagnosis using AI
  • Mathematical Biology Tumor Growth
  • Immune Cell Function and Interaction
  • Long-Term Effects of COVID-19
  • Acute Ischemic Stroke Management
  • Respiratory Support and Mechanisms
  • Bioinformatics and Genomic Networks

Institut de génétique et de biologie moléculaire et cellulaire
2022-2025

Inserm
1993-2025

Centre National de la Recherche Scientifique
2022-2025

Sun Yat-sen University
2024-2025

Université de Strasbourg
2025

Capital Medical University
2019-2025

Beijing YouAn Hospital
2019-2025

Sun Yat-sen University Cancer Center
2025

China Pharmaceutical University
2017-2024

Air Force Medical University
2023-2024

The safety of CRISPR (clustered regularly interspaced short palindromic repeats)-based genome editing in the context human gene therapy is largely unknown. CCR5 a reasonable but not absolutely protective target for cure immunodeficiency virus type 1 (HIV-1) infection, because CCR5-null blood cells are resistant to HIV-1 entry. We transplanted CRISPR-edited CCR5-ablated hematopoietic stem and progenitor (HSPCs) into patient with infection acute lymphoblastic leukemia. leukemia was complete...

10.1056/nejmoa1817426 article EN New England Journal of Medicine 2019-09-11

Substantial heterogeneity exists within cervical cancer that is generally infected by human papillomavirus (HPV). However, the most common histological subtype of cancer, squamous cell carcinoma (CSCC), poorly characterized regarding association between its and HPV oncoprotein expression. We filtered out 138 CSCC samples with infection HPV16 only as first step; then we compressed E6/E7 expression HPVpca correlated immunological profiling based on supervised clustering to discover subtypes...

10.1016/j.neo.2019.04.003 article EN cc-by-nc-nd Neoplasia 2019-05-02

Stratification of cancer patients into distinct molecular subgroups based on multi-omics data is an important issue in the context precision medicine. Here, we present MOVICS, R package for integration and visualization subtyping. MOVICS provides a unified interface 10 state-of-the-art integrative clustering algorithms, incorporates most commonly used downstream analyses subtyping researches, including characterization comparison identified subtypes from multiple perspectives, verification...

10.1093/bioinformatics/btaa1018 article EN Bioinformatics 2020-11-25

The heterogeneity of the immune microenvironment leads to different responses in checkpoint blockade therapy. We aimed propose a robust molecular classification system investigate relevance subtype and prognosis prostate cancer patients, as well therapeutic response A total 1,557 patients were enrolled, including 69 real‐world samples from our institute (titled AHMU‐PC cohort). non‐negative matrix factorization algorithm was employed virtually microdissect patients. enrichment characterized...

10.1002/1878-0261.12887 article EN cc-by Molecular Oncology 2020-12-18

Immunotherapy is a potential way to save the lives of patients with bladder cancer, but it only benefits approximately 20% them. A total 4,028 cancer were collected for this study. Unsupervised non-negative matrix factorization and nearest template prediction algorithms employed classification. We identified immune non-immune classes from The Cancer Genome Atlas Bladder Urothelial Carcinoma (TCGA-BLCA) training cohort. 150 most differentially expressed genes between these two extracted,...

10.1016/j.omto.2021.02.001 article EN cc-by-nc-nd Molecular Therapy — Oncolytics 2021-02-05

Abstract Clear cell renal carcinoma (ccRCC) is a heterogeneous tumor with different genetic and molecular alterations. Schemes for ccRCC classification system based on multiomics are urgent, to promote further biological insights. Two hundred fifty‐five patients paired data of clinical information, transcriptome expression profiles, copy number alterations, DNA methylation, somatic mutations were collected identification. Bioinformatic analyses performed our team's recently developed R...

10.1002/imt2.147 article EN cc-by iMeta 2023-11-01

Abstract Addition of adjuvant corticosteroid therapy to standard antiviral treatment patients with coronavirus disease (COVID-19) is common in clinical practice. However, evidence scarce regarding the efficacy corticosteroids who are critically ill. We retrospectively evaluated effects on outcome 244 ill COVID-19, using a risk stratification model that adjusts for potential differences between steroid group (n=151) and non-steroid (n=93). observed was independent from 28-day mortality,...

10.1101/2020.04.07.20056390 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2020-04-11

Abstract Background Crosstalk between genetic, epigenetic, and immune alterations in upper tract urothelial carcinomas their role shaping muscle invasiveness patient outcome are poorly understood. Results We perform an integrative genome- methylome-wide profiling of diverse non-muscle-invasive muscle-invasive carcinomas. In addition to mutations FGFR3 KDM6A , we identify ZFP36L1 as a novel, significantly mutated tumor suppressor gene. Overall, ZFP36 family genes ( ZFP36L2 ) identified 26.7%...

10.1186/s13059-020-02230-w article EN cc-by Genome biology 2021-01-04

Abstract Generative artificial intelligence (AI) holds immense potential for medical applications, but the lack of a comprehensive evaluation framework and methodological deficiencies in existing studies hinder its effective implementation. Standardized assessment guidelines are crucial ensuring reliable consistent generative AI healthcare. Our objective is to develop robust, standardized tailored evaluating performance contexts. Through rigorous literature review utilizing Web Sciences,...

10.1002/imo2.7 article EN cc-by iMetaOmics. 2024-07-02

BackgroundTo achieve imaging report standardization and improve the quality efficiency of intra-interdisciplinary clinical workflow, we proposed an intelligent layout system (IILS) for a decision support system-based ubiquitous healthcare service, which is lung nodule management using medical images.MethodsWe created IILS based on deep learning workflow optimization identification nodules. Our utilized plus adaptive auto tool, trained tested neural network with data from all main CT...

10.1016/j.ebiom.2019.05.040 article EN cc-by-nc-nd EBioMedicine 2019-05-23

BackgroundInterstitial lung disease requires frequent re-examination, which directly causes excessive cumulative radiation exposure. To date, AI has not been applied to CT for enhancing clinical care; thus, we hypothesize may empower with intelligence realize automatic and accurate pulmonary scanning, thus dramatically decrease medical exposure without compromising patient care.MethodsFacial boundary detection was realized by recognizing adjacent jaw position through training testing a...

10.1016/j.ebiom.2020.102724 article EN cc-by-nc-nd EBioMedicine 2020-04-01

At present, the overall genetic and epigenetic effects of Krüppel-like factors (KLFs) on prostate cancer (PCa) remain unclear. Therefore, we systematically investigated molecular differences in KLFs transcription expression, promoter methylation alteration. Univariate multivariate Cox proportional hazard regression was used to analyse effect RFS establish prognostic signature TCGA cohort, MSKCC GSE116918 cohorts employed validate signature. Biological pathway enrichment potential response...

10.1111/jcmm.15242 article EN cc-by Journal of Cellular and Molecular Medicine 2020-04-13

The efficacy of immune checkpoint inhibitors varies in clear-cell renal cell carcinoma (ccRCC), with notable primary resistance among patients. Here, we integrate epigenetic (DNA methylation) and transcriptome data to identify a ccRCC subtype characterized by cancer-specific promoter hypermethylation silencing Polycomb targets. We develop validate an index methylation-based (iMES) that predicts inhibition (ICI) the BIONIKK trial. High iMES is associated VEGF pathway silencing, endothelial...

10.1016/j.xcrm.2023.101287 article EN cc-by-nc-nd Cell Reports Medicine 2023-11-01

Background Endogenous retrovirus (ERV) elements are genomic footprints of ancestral retroviral infections within the human genome. While dysregulation ERV transcription has been linked to immune cell infiltration in various cancers, its relationship with checkpoint inhibitor (ICI) response solid tumors, particularly metastatic clear-cell renal carcinoma (ccRCC), remains inadequately explored. Methods This study analyzed patients ccRCC from two prospective clinical trials, encompassing 181...

10.1136/jitc-2024-010386 article EN cc-by-nc-nd Journal for ImmunoTherapy of Cancer 2025-01-01

442 Background: In the U.S., racial disparities in renal cell carcinoma (RCC) are documented for common histologies, highlighting differences incidence and outcomes between Black non-Black patients. Such underexplored European populations, especially across a broader histology spectrum within universal healthcare system. We aim to investigate RCC histologies their among patients France. Methods: conducted retrospective cohort study utilizing UroCCR database, spanning from March 1957 May...

10.1200/jco.2025.43.5_suppl.442 article EN Journal of Clinical Oncology 2025-02-10

Abstract Purpose: Collecting duct carcinoma (CDC) is a rare and aggressive subtype of renal carcinoma, posing significant challenges in diagnosis treatment. Current treatment relies on platinum-based chemotherapy, yet clinical outcomes remain poor. While targeted therapies immune checkpoint inhibitors (ICIs) show promise clear-cell cell (ccRCC), they have not been evaluated CDC, their efficacy remains speculative. This underscores pressing need for personalized approaches, driven by an...

10.1158/1538-7445.am2025-1123 article EN Cancer Research 2025-04-21
Coming Soon ...